Recursion Pharmaceuticals Inc [NASDAQ: RXRX] surged by $0.06 during the normal trading session on Friday and reaching a high of $5.33 during the day while it closed the day at $5.27.
Recursion Pharmaceuticals Inc stock has also loss -2.41% of its value over the past 7 days. However, RXRX stock has declined by -0.38% in the 3 months of the year. Over the past six months meanwhile, it has lost -22.16% and lost -29.36% year-on date.
The market cap for RXRX stock reached $2.14 billion, with 399.15 million shares outstanding and 310.64 million shares in the current float. Compared to the average trading volume of 25.67M shares, RXRX reached a trading volume of 16579568 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Recursion Pharmaceuticals Inc [RXRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RXRX shares is $6.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RXRX stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Recursion Pharmaceuticals Inc shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on July 03, 2025. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Equal-Weight. The new note on the price target was released on May 22, 2023, representing the official price target for Recursion Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $17, while Needham analysts kept a Buy rating on RXRX stock.
The Price to Book ratio for the last quarter was 2.29, with the Price to Cash per share for the same quarter was set at 1.24.
RXRX stock trade performance evaluation
Recursion Pharmaceuticals Inc [RXRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.41. With this latest performance, RXRX shares gained by 20.05% in over the last four-week period, additionally sinking by -22.16% over the last 6 months – not to mention a drop of -22.04% in the past year of trading.
Recursion Pharmaceuticals Inc [RXRX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Recursion Pharmaceuticals Inc [RXRX] shares currently have an operating margin of -960.08% and a Gross Margin at -37.97%. Recursion Pharmaceuticals Inc’s Net Margin is presently recorded at -961.32%.
Return on Equity for this stock declined to -61.70%, with Return on Assets sitting at -61.70%.
Earnings per share (EPS) analysis for Recursion Pharmaceuticals Inc [RXRX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RXRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Recursion Pharmaceuticals Inc go to 25.10%.
Recursion Pharmaceuticals Inc [RXRX]: Institutional Ownership
There are presently around $74.16%, or 78.15%% of RXRX stock, in the hands of institutional investors. The top three institutional holders of RXRX stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 28.14 million shares, which is approximately 11.6199%. BAILLIE GIFFORD & CO, holding 26.59 million shares of the stock with an approximate value of $$199.42 million in RXRX stocks shares; and BAILLIE GIFFORD & CO, currently with $$161.67 million in RXRX stock with ownership which is approximately 8.9004%.
